Dopamine inhibits inositol phosphate production, arachidonic acid formation, and corticosteroid release by frog adrenal gland through a pertussis toxin-sensitive G-protein.
We have previously shown that dopamine-evoked inhibition of corticosteroid production from adrenocortical cells is mediated through a decrease in prostaglandin biosynthesis. Since the catecholamine did not alter the stimulatory effect of arachidonic acid, it was proposed that dopamine may inhibit the formation of arachidonate from glycerophospholipids. To test this hypothesis, the effect of dopamine on phosphoinositol lipid metabolism was investigated in frog interrenal (adrenal) tissue. In [3H]myo-inositol-prelabeled frog interrenal slices, a short pulse of dopamine (50 microM) induced a biphasic effect on inositol phosphate production: a transient (1-min) increase, followed by a sustained inhibition. Concurrently, dopamine induced a transient reduction followed by a sustained increase in polyphosphoinositides. A 10-min pulse of the D2 dopamine receptor agonist apomorphine (50 microM) elicited a significant inhibition of basal levels of inositol phosphates (tris-, bis-, and mono-), and an increase in plasma membrane phosphoinositol lipid contents. The inhibitory effect of dopamine on inositol phosphate formation and corticosteroid release was abolished by a 24-h incubation of interrenal slices with pertussis toxin. In [3H]arachidonic acid-prelabeled interrenal slices, dopamine also decreased diacylglycerol (DG) and arachidonic acid (AA) concentrations. A delay of 1 min was observed between inhibition of DG and arachidonate, suggesting that AA is probably generated from DG. We conclude that in the adrenal cortex, activation of dopamine D2 receptors is coupled to a phosphoinositide-specific phospholipase-C mediated via a pertussis toxin-sensitive G-protein. Taken together, our data indicate that inhibition of inositol phosphate and AA formation is one of the mechanisms by which dopamine controls corticosteroid production by adrenocortical cells.
Morra
M
M
European Institute for Peptide Research, CNRS URA 650, UA INSERM, Université de Rouen, Mont-Saint-Aignan, France.
Leboulenger
F
F
Desrues
L
L
Tonon
M C
MC
Vaudry
H
H
D000305:Adrenal Cortex Hormones / Q000037:antagonists & inhibitors*; D000311:Adrenal Glands / Q000378:metabolism*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors*; D004075:Diglycerides / Q000037:antagonists & inhibitors; D004298:Dopamine / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000502:physiology*; D007295:Inositol Phosphates / Q000037:antagonists & inhibitors*; D008297:Male; D037342:Pertussis Toxin; D010743:Phospholipids / Q000378:metabolism; D011895:Rana ridibunda; D010566:Virulence Factors, Bordetella / Q000494:pharmacology*
D000305:Adrenal Cortex Hormones; D001095:Arachidonic Acids; D004075:Diglycerides; D007295:Inositol Phosphates; D010743:Phospholipids; D010566:Virulence Factors, Bordetella; D016718:Arachidonic Acid; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins; D001058:Apomorphine; D004298:Dopamine